Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable …,

… today announced data from the ongoing ARROW clinical trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC), …, … today announced data from the ongoing ARROW clinical trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC), …, Read More

Scroll to Top